Disseminated, metastatic cancer is frequently incurable. Targeted α-particle emitters hold
great promise as therapeutic agents for disseminated disease. 225Ac is a radionuclide …

Purpose Highly cytotoxic α-particle radiotherapy delivered by tumor-selective nanocarriers is
evaluated on metastatic Triple Negative Breast Cancer (TNBC). On vascularized tumors, the …

Targeted α-particle emitters are promising therapeutics for micrometastatic disease.
Actinium-225 has a 10-day half-life and generates a total of four α-particles per parent decay …

Targeted α-particle emitters hold great promise as therapeutics for micrometastatic disease.
Because of their high energy deposition and short range, tumor targeted α-particles can …

Increasing attention is given to personalized tumour therapy, where α-emitters can
potentially play an important role. Alpha particles are ideal for localized cell killing because …

Background: Liposomes carrying chemotherapeutics have had some success in cancer
treatment and may also be suitable carriers for therapeutic radionuclides. This study was …

Purpose For the treatment of cancer, the therapeutic potential of short-range, low-energy
Auger-electron emitters, such as 125 I, is getting progressively wider recognition. The …

Background: Targeted liposomes can be broadly defined as liposomes that are engineered
to interact with a particular population of cells with the objective of delivering a payload or …

The α-particle emitting radionuclides 223Ra (t1 2= 11.4 d), 224Ra (t1 2= 3.6 d), and 225Ac
(t1 2= 10.0 d) may have a broad application in targeted radiotherapy provided that they …

Diffusion limitations on the penetration of nanocarriers in solid tumors hamper their
therapeutic use when labeled with α-particle emitters. This is mostly due to the α-particles' …